Skip to content

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
CTO
Citius Oncology, Inc.CTOR
400M+300%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
120M0.0%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$8K+14.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1.7B+22.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s common stock?
TuHURA Biosciences, Inc. (HURA) reported common stock of $63.58K in Q1 2026.
How has TuHURA Biosciences, Inc.'s common stock changed year-over-year?
TuHURA Biosciences, Inc.'s common stock increased by 45.6% year-over-year, from $43.68K to $63.58K.
What is the long-term trend for TuHURA Biosciences, Inc.'s common stock?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s common stock has grown at a 209.6% compound annual growth rate (CAGR), from $2K to $59.34K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).